



PRESS RELEASE

		Ref	Diag.05.07
Corporate Inquiries	Erik Christensen, Chief Executive Officer DiaGenic ASA, Grenseveien 92, NO-0663 Oslo, Norway Tel +47 95939918 Email: erik.christensen@diagenic.com Jean-Pol Detiffe, Chief Executive Officer DNA Vision, Avenue Georges Lemaître 25, B-6041 Charleroi, Belgium Tel +32 71378527 Email: jp.detiffe@dnavision.be		
Media Inquiries	For DiaGenic Richard Hayhurst, Hayhurst Media Tel +44 (0) 7711821527 Email: richard@hayhurstmedia.com For DNA Vision Michael Herman, DNA Vision Tel +32 71378527 Email: m.herman@dnavision.be		

DIAGENIC PARTNERS WITH DNA Vision TO OFFER FIRST BREAST CANCER AND ALZHEIMER'S GENE-EXPRESSION BLOOD TESTS

OSLO. – November 28 2008 –DiaGenic ASA (OSL:DIAG) today announced that it has signed a service provider agreement with DNA Vision, a leading panEuropean provider of gene expression-based diagnostic testing and services. With this laboratory service and following CE marking scheduled in early 2009, DiaGenic will be able to offer healthcare providers and patients in Europe its innovative blood-based gene-expression test for early detection of breast cancer and for Alzheimer's disease in a CLIA/ISO17025 certified environment.

"This agreement with DNA Vision will provide us with the ideal launch platform across Europe for the blood based tests for early detection of breast cancer and Alzheimer's disease" said DiaGenic CEO Erik Christensen, M.D., Ph.D., "We are currently introducing the breast cancer test in India. The key advantages of our tests are the ease of sample collection– and the ability to detect early signs of disease. However, quality control is equally important in

generating provider and patient confidence. We therefore regard DNAVision as an ideal partner since their testing facilities for molecular diagnostics comply with the most advanced quality standards in Europe.”

“We are delighted to provide the diagnostic testing arm for DiaGenic in Europe for the tests for early detection of breast cancer and Alzheimer’s disease. We are convinced that such tests are laying the basis for new levels of diagnostic services that will benefit overall healthcare provision in Europe” said Jean-Pol Detiffe, CEO of DNAVision. “This agreement is also continuing confirmation that DNAVision has become the partner of choice for biotech companies who want to step into the diagnostic market without facing long IVD application procedures, but with the help of a quality certified service provider generating data available for clinical and diagnostic purposes.”

“In parallel to this agreement, we are finalizing the distribution channels in preparation for a full European launch in early next year following CE marking of both the breast cancer and the Alzheimer’s disease test”, concluded Dr Christensen.

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer's disease has been identified. The company has been granted patents in the U.S. and Europe. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com

About DNAVision

DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services. DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment (First European laboratory to be ISO17025 accredited). DNAVision is a spin-off of University of Brussels and Institute of Pathology and Genetics. More information on DNAVision’s service portfolio can be found on www.dnavision.be

###